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AbstrACt
Objective Valid measures of appearance concern are 
needed in systemic sclerosis (SSc), a rare, disfiguring 
autoimmune disease. The Derriford Appearance 
Scale-24 (DAS-24) assesses appearance-related 
distress related to visible differences. There is 
uncertainty regarding its factor structure, possibly due 
to its scoring method.
Design Cross-sectional survey.
setting Participants with SSc were recruited from 27 
centres in Canada, the USA and the UK. Participants who 
self-identified as having visible differences were recruited 
from community and clinical settings in the UK.
Participants Two samples were analysed (n=950 
participants with SSc; n=1265 participants with visible 
differences).
Primary and secondary outcome measures The 
DAS-24 factor structure was evaluated using two 
scoring methods. Convergent validity was evaluated 
with measures of social interaction anxiety, depression, 
fear of negative evaluation, social discomfort and 
dissatisfaction with appearance.
results When items marked by respondents as ‘not 
applicable’ were scored as 0, per standard DAS-24 
scoring, a one-factor model fit poorly; when treated as 
missing data, the one-factor model fit well. Convergent 
validity analyses revealed strong correlations that were 
similar across scoring methods.
Conclusions Treating ‘not applicable’ responses as 
missing improved the measurement model, but did not 
substantively influence practical inferences that can be 
drawn from DAS-24 scores. Indications of item redundancy 
and poorly performing items suggest that the DAS-24 
could be improved and potentially shortened.
IntrODuCtIOn
Systemic sclerosis (SSc or scleroderma) is an 
autoimmune disease characterised by skin 
thickening, internal organ fibrosis, disability, 
significant appearance changes and disfig-
urement in highly visible parts of the body.1 
Common physical appearance concerns 
include hypopigmentation and hyperpig-
mentation of the skin, changes to skin 
texture, telangiectasia, hand contractures, 
sclerodactyly, calcinosis and altered facial 
features, including a pinched appearance to 
strengths and limitations of this study
 ► This is the first study to evaluate concerns 
regarding the scoring methodology of items with 
a ‘not applicable’ response option in the Derriford 
Appearance Scale-24 (DAS-24).
 ► Two large samples of individuals with physical 
disfigurement were drawn from clinical and 
community settings.
 ► This study used confirmatory factor analysis, a 
contemporary and theory-driven approach to testing 
factor structure and goodness of fit, with a weighted 
least squares means and variance adjusted 
estimator which performs well with observed 
variables on an ordinal scale.
 ► The two samples did not include the convergent 
validity measures used in the original DAS-24 study.
 ► Convergent validity could not be compared between 
the two samples due to differences in the measures 
taken for each sample.
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the nose and eyes, loss of lip contour with thinning of 
the lips and a decreased ability to fully open the mouth. 
Treatments may also lead to appearance changes: certain 
immunosuppressant drugs can cause hair loss and long-
term steroid use may contribute to a Cushingoid facial 
appearance.2 
Visible differences in appearance are associated with 
distress, poorer self-esteem, body image problems and 
diminished quality of life.3 In SSc, visible differences 
are common4 and associated with greater body image 
dissatisfaction,5–7 poorer psychosocial functioning8 and 
increased anxiety and depression.9 Thus, there is a signif-
icant need to study physical appearance concerns in SSc 
and to validate measures related to appearance in SSc.10 11
The Derriford Appearance Scale-24 (DAS-24),12 13 
the short form of the DAS-59,14 measures distress and 
dysfunction related to physical appearance concerns 
in populations with visible differences such as SSc. The 
DAS-24 is hypothesised to yield a single factor repre-
senting appearance-related distress and dysfunction.13 
In an adult sample of 535 patients with appearance 
concerns, the DAS-24 total score demonstrated internal 
consistency reliability (α=0.92), concurrent validity with 
the DAS-59 criterion measure (r=0.88) and convergent 
validity (rs=0.45–0.66 with measures of anxiety, depres-
sion, social avoidance and distress, fear of negative evalu-
ation, internalised shame).12
However, recent results from 1265 community and clin-
ical participants with visible difference suggested that the 
DAS-24 may not be unidimensional.15 Exploratory factor 
analysis with principal axis factoring and oblique rotation 
revealed two factors: general self-consciousness (18 items) 
and sexual and bodily self-consciousness (six items).15 The 
interfactor correlation was not reported; it is presumed 
to be large given that internal consistency for the total 
score was high (α=0.93). The authors concluded that 
the DAS-24 may be conceptualised as either the original 
unidimensional total score or the two subscale scores.15
One possible explanation for the uncertain factor 
structure may relate to the DAS-24 scoring procedure. 
To complete the measure, respondents first identify and 
describe a part of their appearance that is concerning 
to them (referred to as their ‘feature’). The respon-
dent then rates each item on a 1–4 scale, with higher 
values indicating greater appearance-related distress and 
dysfunction.13 Fourteen items include a ‘not applicable’ 
(NA) option (scored as 0) to accommodate situations 
that are not relevant to a respondent. For example, an 
unemployed respondent might choose NA for the work 
item. Total scores are calculated by summing the items.13 
Thus, respondents who marked many items as NA could 
receive a low total score, even if they report significant 
appearance-related distress and dysfunction on the other 
items.
At the broadest level, NA responses in surveys are best 
considered within the context of missing data.16 Treating 
these responses as very low scores, as is the procedure 
for the DAS-24, could lead to factorial solutions that 
represent an artefact of the NA procedure itself. In the 
two-factor model reported by Moss et al,15 the second 
factor (sexual and bodily self-consciousness) was composed of 
six items, which all had the NA option (distressed at beach, 
avoid communal changing, avoid undressing with partner, 
distressed playing sports/games, distressed by clothing limitations, 
affects sex life). Among these items,15 the NA response was 
chosen an average of 26% of the time (range: 19%–36%). 
NA was only chosen an average of 13% of the time (for 
the items with the NA option) that loaded on the first 
factor of general self-consciousness (range: 6%–32%). It 
is also worth noting that several items without the NA 
option (eg, distressed at reflection) loaded on the first factor 
(general self-consciousness) but conceptually match the 
second factor (sexual and bodily self-consciousness). Thus, it 
is possible that the two-factor solution may at least partly 
reflect shared method variance, rather than the concep-
tual coherence of two factors.
Given these concerns, the aim of this study was to eval-
uate two different scoring methods to determine whether 
the standard scoring procedure affects the factor struc-
ture and convergent validity of DAS-24 scores. The first 
aim was to evaluate the one-factor model in a sample 
of patients with SSc and Moss et al’s visible difference 
sample15 using the two scoring methods. In the standard 
method, as described in the DAS-24 manual13 and existing 
studies, NA responses were scored as 0. In the missing 
method, NA responses were modelled as missing data. It 
was hypothesised that model fit for the one-factor model 
scored according to the missing method would be supe-
rior in both samples. The second aim was to evaluate the 
convergent validity of DAS-24 scores calculated via both 
scoring methods in the SSc sample. It was hypothesised 
that DAS-24 scores would have a strong association with 
satisfaction with appearance (rs≥0.5), moderate to strong 
associations with fear of negative evaluation and social 
interaction anxiety (r≈0.4–0.5) and a moderate associa-
tion with depressive symptomatology (r≈0.3). It was also 
hypothesised that correlations would be significantly 
stronger when the missing method was used.
MethODs
Patients and procedure
SSc sample
Patients enrolled in the Scleroderma Patient-centred 
Intervention Network (SPIN) Cohort completed study 
questionnaires from April 2014 through April 2016. 
Research Ethics Committee approval of the Jewish 
General Hospital and by the Institutional Review Boards 
of each participating center was obtained. Patients were 
enrolled at 27 centres from Canada, the USA and the 
UK. Eligible participants were1 classified as having SSc 
according to the 2013 American College of Rheuma-
tology/European League Against Rheumatism classifica-
tion criteria17 as confirmed by a SPIN physician,2 at least 
18 years of age,3 able to give informed consent,4 fluent in 
English or French and5 able to respond to questionnaires 
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via the Internet. Physicians or supervised nurse coordi-
nators from SPIN recruiting sites invited eligible patients 
to participate, obtained written informed consent and 
completed a medical data form to initiate patient regis-
tration in the study. After registration, an automated 
welcome email was sent to patients with instructions to 
activate their SPIN account and complete the online 
questionnaires. SPIN participants complete outcome 
measures online on enrolment and subsequently every 
3 months; the present study includes only the baseline 
assessment.
Visible difference sample
Data were obtained from the study by Moss et al.15 
Respondents were community and clinical participants 
who self-identified as being ‘visibly different’ recruited 
through advertisements, general practice physicians and 
outpatient medical clinics including prosthetics, derma-
tology, ophthalmology, general plastics, burn, ear/nose/
throat clinics (including cleft lip and palate), oncology 
and laser treatment. Data were downloaded from https:// 
peerj. com/ articles/ 1070/# supplemental- information.
Main study measure (ssc sample and visible difference 
sample) 
DAS-2412 13 contains 24 items with a response scale from 
1 to 4; 10 items have only this scale; 14 items also include 
a NA option (scored as 0). Total scores range from 10 to 
96, with higher scores indicating a greater level of appear-
ance-related distress and dysfunction. Good internal 
consistency reliability and validity has been reported.13 
In both of the present samples, internal consistency 
reliability calculated using the standard method was: SSc 
α=0.92; visible difference α=0.96.
Convergent validity measures (ssc sample)
Social Interaction Anxiety Scale-6 (SIAS-6)18 is the 
six-item short form of the SIAS19 and measures anxiety 
resulting from social interactions. Respondents rate state-
ments (eg, I feel tense if I am alone with just one person) on 
a scale from 0 to 4. Total scores range from 0 to 24, with 
higher scores indicating greater social anxiety. Internal 
consistency reliability in the SSc sample was α=0.89.
Patient Health Questionnaire-8 (PHQ-8)20 is an adapted 
version of the PHQ-9,21 a measure of depression that has 
been validated for use in SSc.22 Frequency of symptoms (eg, 
Little interest or pleasure in doing things) over the past 2 weeks is 
rated on a scale from 0 to 3. Total scores range from 0 to 24, 
with higher scores indicating more symptoms of depression. 
Internal consistency reliability in the SSc sample was α=0.89.
Brief Fear of Negative Evaluation Scale-Revised (BFNE-
II)23 is a 12-item short form of the BFNE24 that assesses 
apprehension and distress of being negatively evaluated. 
Respondents rate statements (eg, I worry about what kind of 
impression I make on people) on a scale from 1 to 5. Total scores 
range from 12 to 60, with higher scores indicating greater 
fear of negative evaluation. Internal consistency reliability in 
the SSc sample was α=0.98.
Satisfaction with Appearance Scale (SWAP)25 is a 14-item 
measure of satisfaction with appearance developed for burn 
survivors,25 then adapted for SSc and validated.6 9 Respon-
dents rate statements about their physical appearance or 
social discomfort on a scale from 0 to 6. The SWAP yields 
two subscale scores: social discomfort (eg, My appearance makes 
other people uncomfortable) which reflects social discomfort 
related to body dissatisfaction (six items; range 0–36 with 
higher scores indicting greater discomfort) and dissatis-
faction with appearance (eg, I am satisfied with the appearance 
of my face) which reflects dissatisfaction with various body 
parts (eight items; range 0–48 with higher scores indicating 
greater dissatisfaction). The SWAP has demonstrated good 
measurement properties in SSc.7 9 Internal consistency reli-
ability in the SSc sample was: social discomfort α=0.93, dissatis-
faction with appearance α=0.92.
ssc measures (ssc sample)
Years since the first non-Raynaud’s phenomenon symptoms 
was calculated by taking the deviation between the date that 
forms were completed online and the date of a patient’s first 
non-Raynaud’s symptom. This method is recommended as 
an approximation of the onset of SSc.26
The Modified Rodnan Skin Score (mRSS),27 a clini-
cian-administered indicator of skin disease severity, is calcu-
lated by measuring the extent and severity of skin thickening 
on 17 body surfaces by palpation on scale ranging from 0 to 
3. Total scores range from 0 to 51 with higher scores indi-
cating greater severity.
SSc disease subtype is classified by the pattern and 
severity of skin fibrosis.28 The limited subtype is character-
ised by skin involvement distal to the elbows and knees, 
slower fibrosis and milder internal organ involvement. 
Limited patients without cutaneous involvement are clas-
sified as having sine SSc. The diffuse subtype is character-
ised by more extensive skin thickening involving proximal 
extremities and/or the trunk in addition to proximal 
involvement, rapidly progressing fibrosis and more signif-
icant internal organ involvement.
Appearance-related variables documented by study physi-
cians included telangiectasia (facial or any), skin pigmen-
tation changes (facial or any) and hand contractures. 
Telangiectasia involves dilated superficial blood vessels that 
appear as red lines or patches on the skin that collapse 
on pressure and fill slowly when pressure is released. Skin 
pigmentation changes were defined as hyperpigmenta-
tion or hypopigmentation. Disfigurement due to hand 
contractures (tightening around the proximal interphalan-
geal joints, metacarpals and/or wrists that limits range of 
motion) was defined as the percentage of limitation in range 
of motion, categorised as none/mild (0%–25%), moderate 
(25%–50%), or severe (>50%).
Data analysis
Scoring
DAS-24 scores were calculated using two methods. The stan-
dard method scored the 14 items with the NA option using 
the 0–4 metric described in the manual.13 That is, 0 was 
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used when a person chose NA for an item and 1–4 indicated 
that a person had chosen that response option. The second 
method, the missing method, scored the 14 items with the NA 
option such that NA responses were treated as missing data 
(described below in the section Analytic Strategy) and 1–4 
indicated that a person had chosen that response.
Analytic strategy
Confirmatory factor analysis (CFA) was conducted in Mplus 
V.7.229 to examine the one-factor model in the SSc and visible 
difference samples using both scoring methods. Weighted 
least squares means and variance adjusted (WLSMV) esti-
mation, which is robust to non-normal and non-indepen-
dent data, was used to handle the ordinal rating scale of 
the DAS-24. Missing data were handled using a variation 
of the full information maximum procedure employed for 
WLSMV estimation in Mplus which is analogous to pairwise 
present analysis.29 Models were evaluated according to statis-
tical and descriptive indices, given that χ2 tests have signif-
icant limitations, including a high degree of dependence 
on sample size.30 Following Bentler’s31 recommendations, 
the root mean square error of approximation (RMSEA)32 
and Comparative Fit Index (CFI)33 were evaluated. Cut-off 
thresholds were based on commonly used recommenda-
tions.34 For the RMSEA, values. 0.06–0.08 were interpreted 
as acceptable model fit, with values <0.06 indicating close fit. 
For the CFI, values. 0.90–0.95 were interpreted as acceptable 
model fit, with values >0.95 indicating close fit. Standardised 
factor loadings were evaluated and compared across the two 
scoring methods.
Convergent validity analyses of the DAS-24 were 
conducted using the SSc sample. In order to capture differ-
ences between scoring methods, two DAS-24 averages were 
computed for each respondent. To represent the standard 
method, values for all 24 items were totaled (NA responses 
were scored as 0) and divided by 24 to yield a standard 
method average score (possible range 0.42–4.00). To represent 
the missing method, values for all items for which a respon-
dent chose a numeric value were totaled (10–24 items) and 
divided by the total number of items that were answered to 
yield a missing method average score (possible range 1.00–4.00). 
Bivariate correlations between both average scores (standard 
and missing) and each convergent validity measure (SIAS-6, 
PHQ-8, BFNE-II, SWAP) were evaluated in SPSS V.24.0.35 
Correlation coefficients for each scoring procedure were 
compared using methods described by Steiger36 via an 
online calculator.37
results
Description of ssc and visible difference samples
Characteristics of the SSc sample (n=950) are reported in 
table 1. The majority of participants were female (87%), 
married (85%) and white (73%). Age ranged from 18 to 
84 years (M=55.5). The average skin thickening (mRSS 
score) was 8.0 (range 0–48); this differed by disease 
subtype (diffuse M=13.6 (SD=10.4), limited/sine M=4.2 
(SD=4.2)). Nearly three-quarters of the sample reported 
telangiectasia, one-third reported skin pigmentation 
changes and one-third reported hand contractures.
Detailed characteristics of the visible difference sample 
(n=1265; community n=614, clinic n=651) are available 
elsewhere.15 The majority of participants were female 
(69%), married (62%) and white (81%). Age ranged 
from 18 to 91 years (M=47.3).
Description of DAs-24 scores: ssc sample and visible 
difference sample
DAS-24 scores were lower for the SSc (M=35.7, SD=13.7) 
than visible difference (M=41.7, SD=16.3) sample 
(Hedges’ g=0.39). A description of the patterns of NA 
responses is available in table 2. In the SSc sample, the 
proportion of NA responses ranged from 11% to 49% 
per item; in the visible difference sample, the propor-
tion of NA responses ranged from 6% to 36% per item. 
Item 5 (self-consciousness affects work; SSc=44%, visible 
difference=32%) and item 16 (distressed playing sports/
games; SSc=49%, visible difference=36%) had the highest 
percentage of NA responses.
CFA: ssc sample
Overall fit for the one-factor model scored according to 
the standard method was not adequate (χ2(252)=2415.6, 
P<0.001; CFI=0.896, RMSEA=0.095; table 3). Standardised 
factor loadings (table 2) were statistically significant and 
ranged from small to large (λs=0.18–0.79, P<0.001). When 
the missing method was used, overall fit for the one-factor 
model was improved and good (χ2(252)=1188.0, P<0.001; 
CFI=0.958, RMSEA=0.063; table 3). Standardised factor 
loadings (table 2) were statistically significant and large 
(λs=0.62–0.84, P<0.001).
The factor loadings for several items with a high number 
of NA responses were larger when scored according to 
the missing method. These differences can be seen for item 
5 (% missing=44%; Standard λ=0.45, Missing λ=0.80), item 
6 (% missing=30%; Standard λ=0.48, Missing λ=0.77), item 
12 (% missing=40%; Standard λ=0.36, Missing λ=0.64), 
item 15 (% missing=26%; Standard λ=0.44, Missing 
λ=0.72) and item 16 (% missing=49%; Standard λ=0.18, 
Missing λ=0.71).
CFA: visible difference sample
Overall fit for the one-factor model scored according to 
the standard method was not adequate (χ2(252)=4593.3, 
P<0.001; CFI=0.870, RMSEA=0.117; table 3). Stan-
dardised factor loadings (table 2) were statistically signif-
icant and ranged from moderate to large (λs=0.41–0.82, 
P<0.001). When the missing method was used, overall 
fit for the one-factor model was improved and good 
(χ2(252)=2061.5, P<0.001; CFI=0.952, RMSEA=0.075; 
table 3). Standardised factor loadings (table 2) were 
statistically significant and large (λs=0.62–0.84, P<0.001).
The factor loadings for several items with high a 
high number of NA responses were larger when scored 
according to the missing method. These differences can be 
seen for item 5 (% missing=32%; Standard λ=0.58, Missing 
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λ=0.77), item 15 (% missing=28%; Standard λ=0.41, 
Missing λ=0.72) and item 16 (% missing=36%; Standard 
λ=0.43, Missing λ=0.74).
Convergent validity: ssc sample
Correlations describing the relationship between average 
DAS-24 scores (standard and missing) and scores of social 
interaction anxiety, depression, fear of negative evalu-
ation, social discomfort and dissatisfaction with appear-
ance are in table 4. Correlations for the standard method 
average score were large and statistically significant 
(rs=0.44–0.69). Correlations for the missing method average 
score were large and statistically significant (rs=0.47–
0.72). In all but one case, the missing method correlations 
were significantly larger than the standard method correla-
tions, but the magnitude of differences were very small 
(0.02–0.07).
DIsCussIOn
Confirmatory factor analyses revealed that a one-factor 
DAS-24 model fit poorly when using the standard method, 
but that the one-factor model fit well when using the 
missing method in both the SSc and visible difference 
samples. Correlations with measures of convergent 
validity calculated using the missing method were signifi-
cantly larger than those calculated using the standard 
method, but the implications for inferences drawn from 
DAS-24 scores are likely negligible given the small magni-
tude of differences.
The finding that a one-factor model fit well when 
items were scored in a manner more logically consis-
tent with their intent (missing method) supports the orig-
inal conceptualisation of the DAS-24 as representing 
a single latent construct of distress and dysfunction 
related to appearance.13 This also adds to a growing 
literature suggesting that model-based missingness 
methods are the most suitable solution for dealing with 
NA responses.16 On one hand, this would suggest that 
parameter estimates for models based on the standard 
method are misleading and that use of the DAS-24, which 
includes items that are not relevant to some respon-
dents, should be discontinued. On the other hand, 
Table 1 Systemic sclerosis sample description (n=950)
M±SD or n (%)
Demographic characteristics
Age in years (n=947) 55.48±12.05
Language
  English 882 (92.8)
  French 68 (7.2)
Sex
  Women 827 (87.1)
  Men 123 (12.9)
Race/ethnicity
  White 807 (84.9)
  Black 54 (5.7)
  Other 88 (9.3)
  Missing 1 (0.1)
Marital status 
  Married/partnered 692 (72.8)
  Never married 111 (11.7)
  Divorced/separated 110 (11.6)
  Widowed 37 (3.9)
Employment status 
  Full-time employment 282 (29.7)
  Part-time employment 103 (10.8)
  Unemployed 123 (12.9)
  Homemaker, student, other 439 (46.5)
  Missing 1 (0.1)
Disease characteristics
Years since first non-Raynaud’s 
symptoms (n= 876) 
11.75±8.90
Modified Rodnan Skin Score
(n=759)
7.98±8.71
Disease subtype
  Diffuse 383 (40.3)
  Limited/sine 558 (58.8)
  Not available 9 (0.9)
Telangiectasia (any; n=950)
  Yes 677 (71.3)
  No 257 (27.1)
  Not available 16 (1.7)
Telangiectasia (face; n=677)
  Yes 452 (66.8)
  No 75 (11.1)
  Not available 150 (22.1)
Pigmentation changes (any; n=950)
  Yes 285 (30.0)
  No 600 (63.2)
  Not available 65 (6.8)
Continued
M±SD or n (%)
Pigmentation changes (face; n=285)
 Yes 147 (51.6)
 No 94 (33.0)
 Not available 44 (15.4)
Hand contractures (n=950)
 No/mild (0%–25%) 674 (70.9)
 Moderate (25%–50%) 172 (18.1)
 Severe (>50%) 50 (5.3)
 Not available 54 (5.7)
Table 1 Continued 
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convergent validity coefficients were similar across 
scoring methods, suggesting that use of the existing 
version of the DAS-24, despite its less optimal struc-
ture and scoring method, may not substantively impair 
its utility. Although factor structure is an important 
component of construct validity, it should be consid-
ered in the context of all validity evidence and, in partic-
ular, the extent to which a measure’s internal structure 
affects criterion validity and its practical application.38 
Thus, it appears that scoring NA items as 0 yields 
Table 2 Data missing due to ‘not applicable’ and standardised factor loadings for the one-factor model of the Derriford 
Appearance Scale-24 using the SM and MM for the SSc and visible difference samples
Item
SSc Visible difference
Not 
applicable, n 
(%)
SM
λ
MM
λ
Not 
applicable, n 
(%)
SM
λ
MM
λ
1. Feeling confident – 0.65 0.68 – 0.68 0.71
2. Distressed at reflection – 0.77 0.77 – 0.77 0.79
3. Irritable at home* 207 (21.8) 0.76 0.76 204 (16.1) 0.75 0.80
4. Feel hurt† – 0.78 0.79 77 (6.1) 0.78 0.81
5. Self-consciousness affects work* 415 (43.7) 0.45 0.80 401 (31.7) 0.58 0.77
6. Distressed at beach* 289 (30.4) 0.48 0.77 241 (19.1) 0.64 0.77
7. Misjudged due to appearance* 260 (27.4) 0.65 0.69 237 (18.7) 0.60 0.65
8. Feel feminine/masculine – 0.57 0.62 – 0.57 0.62
9. Self-conscious of appearance* 128 (13.5) 0.73 0.71 79 (6.2) 0.75 0.77
10. Feel irritable – 0.73 0.73 – 0.72 0.74
11. Adopt concealing gestures – 0.68 0.65 – 0.68 0.66
12. Avoid communal changing* 377 (39.7) 0.36 0.64 248 (19.6) 0.55 0.67
13. Distressed in supermarkets/department stores* 113 (11.9) 0.65 0.73 101 (8.0) 0.66 0.74
14. Feel rejected – 0.79 0.79 – 0.82 0.82
15. Avoid undressing with partner* 249 (26.2) 0.44 0.72 351 (27.7) 0.41 0.72
16. Distressed playing sports/games* 462 (48.6) 0.18 0.71 460 (36.4) 0.43 0.74
17. Close into shell – 0.77 0.79 – 0.74 0.75
18. Distressed by clothing limitations* 285 (30.0) 0.67 0.73 343 (27.1) 0.62 0.74
19. Distressed at social events* 104 (10.9) 0.76 0.84 85 (6.7) 0.75 0.84
20. Feel normal – 0.73 0.76 – 0.73 0.76
21. Affects sex life* 266 (28.0) 0.50 0.76 321 (25.9) 0.56 0.77
22. Avoid leaving house – 0.73 0.76 – 0.75 0.78
23. Distressed at others remarks about appearance* 312 (32.8) 0.65 0.71 212 (16.8) 0.67 0.75
24. Avoid pubs/restaurants* 137 (14.4) 0.62 0.78 98 (7.7) 0.59 0.78
*Items with the ‘not applicable’ option.
†This item contained ‘0/not applicable’ responses in the visible difference data but was scored using the 1–4 scale only in the SSc sample; ps 
for all factor loadings <0.001.
MM, missing method (‘not applicable’ scored as missing); SM, standard method (‘not applicable’ scored as 0); SSc, systemic sclerosis. 
Table 3 Goodness of fit statistics for one-factor models of the DAS-24
Data
Scoring 
method χ2 df P value CFI RMSEA (90% CI)
SSc Standard 2415.63 252 <0.001 0.896 0.095 (0.092–0. 099)
Missing 1188.01 252 <0.001 0.958 0.063 (0.059–0. 066)
Visible difference Standard 4593.25 252 <0.001 0.870 0.117 (0.114–0. 120)
Missing 2061.49 252 <0.001 0.952 0.075 (0.072–0. 078)
Note. Standard method: ‘not applicable’ scored as 0; missing method: ‘not applicable’ scored as missing.
CFI, Comparative Fit Index; DAS-24, Derriford Appearance Scale-24; RMSEA, root mean square error of approximation. 
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statistical problems when models are judged by strin-
gent criteria, but that the implications for the overall 
validity of DAS-24 scores using the standard method may 
be of less consequence.
The DAS-24’s reasonably strong functional perfor-
mance, as assessed via convergent validity analyses 
suggests that there is likely excessive redundancy within 
the measure. When items rated as NA were modelled 
using the standard method, factor loadings were substan-
tially impaired, and, for many items, clearly unac-
ceptable. Nonetheless, convergent validity was only 
minimally reduced, and internal consistency reliability 
was very high (SSc α=0.92; visible difference α=0.96). 
It is well-established that very high Cronbach’s alphas 
(eg, α >0.90) tend to reflect overly redundant items.39–42 
Thus, it seems that there is a core group of DAS-24 
items that function well, and the inclusion of unneces-
sary items and even problematically scored items does 
not have a substantive negative impact on the practical 
performance of the measure or clinical inferences that 
can be drawn from it.
Nonetheless, the problems of unnecessary item 
redundancy and problematically scored items are 
concerns in research and clinical contexts because they 
reduce measurement precision and increase survey 
length and time burden on in populations with phys-
ical appearance concerns, like SSc. These concerns are 
particularly salient in collaborative research contexts 
where medical and patient-reported outcome data are 
collected from large numbers of patients across span 
countries, languages and clinical settings, as is the case 
with the SPIN cohort. Research on the DAS-24 should 
focus on reducing the number of items and addressing 
existing scoring issues with the goal of maximising item 
parsimony and retaining the full construct domain of 
distress and dysfunction related to concerns with phys-
ical appearance as previously defined.12 13 Recently, 
optimal test assembly methods have been used to 
shorten measures based on objective, prespecified 
criteria,43 and these methods could be used to identify 
a shorter version of the DAS-24 that performs similarly 
and eliminates its problematic scoring.
This study contributes to the growing literature on the 
DAS-24 using two large samples composed of respon-
dents with diverse physical appearance concerns that 
are generalisable to other visible difference popula-
tions. There are also limitations that should be consid-
ered in the context of the current results. First, the SSc 
data did not contain the convergent validity measures 
used in the original DAS-24 validation study, and thus 
measures of closely related constructs were used as 
proxies. Second, convergent validity analyses could not 
be conducted in the visible difference sample as these 
measures were not available.
In sum, these findings suggest that scoring the DAS-24 
according to the standard method leads to a suboptimal 
measurement model. The missing method yields a supe-
rior one-factor structure but does not lead to substan-
tively different relationships with theoretically related 
constructs. Thus, while it is preferable to treat NA 
responses as missing, particularly in research settings, it 
is unlikely that using the standard method greatly impacts 
the practical interpretation of DAS-24 scores. The 
development of a short form that removes item redun-
dancy while retaining adequate psychometric proper-
ties is needed and would particularly benefit research in 
populations with visible differences in appearance such 
as patients with SSc.
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